Palatin Technologies, Inc. (PTN) stock rallied over 2.10% intraday to trade at $0.2819 a share on AMEX. The stock opened with a gain of 0.68% at $0.272 and touched an intraday high of $0.28, rising 4.41% against the last close of $0.27. The stock went to a low of $0.264 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue872.91 Thousands
5Y Sales Change-
Fiscal Year Ends2021-06-29
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Palatin Technologies, Inc. (AMEX: PTN) stock price is $0.2819 as of the last check on Wednesday, August 10. During the trading session, PTN stock reached the peak price of $0.28 while $0.264 was the lowest point it dropped to.
The AMEX listed PTN is part of Biotechnology industry that operates in the broader Health Care sector. Palatin Technologies, Inc. , a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.
Dr. Carl Spana Ph.D.
Co-Founder, Pres, CEO & Director
Mr. Stephen T. Wills CPA, CPA, MST
CFO, COO, Exec. VP, Treasurer & Sec.
VP of Investor Relations
Mr. Stephen A. Slusher Esq.
Chief Legal Officer
PTN stock traded closed the last session at $0.276, which is $0.005799999999999972 or 2.1006881564650386% lower than its previous close of $0.27. PTN's current trading price is 9.65% lower than its 52-week high of $0.96 where as its distance from 52-week low of 0.25% is -71.24%.
Number of PTN employees currently stands at -. PTN operates from Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ 08512, United States.
Official Webiste of $PTN is: https://palatin.com
PTN could be contacted at PTN operates from Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ 08512, United States, or at phone #609 495 2200 and can also be accessed through its website.
PTN stock volume for the day was 712,575 shares while in the previous session number of PTN shares traded was 585,805 . The average number of PTN shares traded daily for last 3 months was 689.26 Thousands.
The percentage change in PTN stock occurred in the recent session was 2.1006881564650386% while the dollar amount for the price change in PTN stock was $0.005799999999999972.
In the recent session, the day high for PTN stock was $0.28 while the low for PTN stock touched on the day was $0.264.
The market value of PTN currently stands at 62.17 Million with its latest stock price at $0.2819 and 238.81 Million of its shares outstanding.